What patients should know
For people living with post-traumatic stress disorder, finding effective care can involve more than one treatment approach. A development in personalized brain stimulation has added another option for adults and their clinicians to consider.
On June 3, 2026, the U.S. Food and Drug Administration cleared Wave Neuroscience’s MeRT® System as an adjunctive treatment for adults with PTSD.
Olympia Center for TMS & Psychiatry now offers this treatment using Wave Neuroscience MeRT technology with MagVenture™ TMS hardware. Here is what the clearance means—and what patients should understand when considering care.
What changed with this clearance?
Researchers and clinicians have studied transcranial magnetic stimulation, or TMS, for PTSD for many years. Historically, clinicians sometimes treated PTSD using TMS equipment cleared for other conditions, an approach described as off-label use.
The June 2026 decision established a PTSD indication for the MeRT System.
The distinction matters: clearance applies to a specific treatment system and intended use. It does not mean every TMS machine or protocol has FDA clearance for PTSD.
What makes MeRT different?
MeRT stands for Magnetic EEG/ECG Resonance Therapy.
It uses recordings of electrical activity in the brain and heart to help personalize TMS treatment settings. Wave Neuroscience’s software analyzes those recordings and recommends an individualized stimulation frequency.
TMS treatment is then delivered through a magnetic coil positioned against the scalp.
This provides a different way of determining treatment settings. It does not mean that a personalized approach guarantees a better outcome for every patient.
What did the clinical trial show?
The study supporting clearance included 158 adults with PTSD: 77 were assigned to active MeRT treatment and 81 to sham treatment. The study protocol involved approximately 20–25 sessions.
Participants receiving active treatment showed greater improvement than the sham group on both patient-reported and clinician-administered PTSD measures.
No serious adverse events were reported in the study. That finding does not mean treatment is risk-free or suitable for everyone.
The trial evaluated the complete MeRT System against sham treatment. It did not establish that EEG-based personalization alone was responsible for the results or that MeRT is superior to every other TMS approach.
These findings describe a study population, but individual responses can differ.
What does “adjunctive treatment” mean?
Adjunctive treatment is used alongside other care.
For PTSD, a treatment plan may include trauma-focused psychotherapy, medication, or other support. MeRT’s clearance does not mean patients should discontinue those treatments.
A clinician can review your current care, previous response to treatment, symptoms, and health history to determine whether MeRT should be considered as an additional option.
Does clearance mean insurance will pay?
FDA clearance does not automatically establish insurance coverage.
Insurance policies, authorization requirements, and patient costs may vary. Before beginning treatment, ask about your benefits, any required authorization, and your expected financial responsibility.
Our staff can help review those questions, although authorization and payment cannot be guaranteed.
What does this mean for patients in our community?
At Olympia Center for TMS & Psychiatry, our experience with TMS and PTSD care predates this clearance.
We work with people affected by many forms of trauma, including first responders, injured workers, veterans, service members, military families, and civilian trauma survivors.
MeRT adds another treatment option for adults to discuss with our clinical team. An evaluation can help clarify whether it may fit your needs and how it would work alongside your existing care.
For details about the treatment process, insurance, and getting started, visit our TMS treatment for PTSD page.
To ask about an evaluation, call (360) 539-1736 or contact our team.
Source
U.S. Food and Drug Administration: MeRT System clearance and clinical summary, K260402.
Best of South Sound 2026 Gold Winner